Oncolytics Biotech (NASDAQ: ONCY) has announced the appointments of John McAdory as executive vice president (EVP), strategy and operations, and Yujun Wu as vice president (VP), head of biostatistics.
According to Oncolytics, these appointments are expected to enhance the company’s operational, clinical, and regulatory capabilities as it advances registration-directed development programs in pancreatic, colorectal, and anal cancers.
Mr. McAdory brings extensive experience leading late-stage oncology programs, particularly in the oncolytic virus space. Mr. Wu joins Oncolytics to lead biostatistics, bringing deep expertise in statistical strategy, regulatory interactions, and late-stage trial design.
In a statement, Jared Kelly, CEO of Oncolytics, commented, “John’s background running complex, late-stage oncology trials, makes him exceptionally well-suited to lead Oncolytics’ next phase of execution. As we progress toward pivotal and registration-enabling studies in anal, pancreatic, and colorectal cancers, his experience will be critical to ensuring disciplined execution, speed, and regulatory alignment.”
Mr. Kelly added, “Yujun’s experience designing and supporting late-stage studies and interacting with regulators significantly strengthens our internal capabilities. As we pursue accelerated approval strategies and pivotal trials, high-quality statistical leadership is essential, and Yujun brings that expertise at a critical time for the company.”
